Lexicon Pharmaceuticals, Inc.’s Post

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes. To view the full press release, visit our website: bit.ly/4bdnVUj #LexiconNews #T1D #Type1Diabetes

  • No alternative text description for this image

Terrific to know a company who stays dedicated to supporting T1D's.

Lysianne Jones

Experienced Sales & Life Science Professional | 15 Years in Sales | EH&S & project Manager | Certified Pharmaceutical Sales Rep & Life/Career Coach | Diabetes Patient Advocate

1w

Amazing strides

Like
Reply
Kevin Roberts

Executive Cardiovascular Sales Specialist

3w

Here we go!!! 💊💪🏾👊🏾

Joseph Johnson

Executive Cardiovascular Specialty Sales Rep at Novartis

4w

Love this

Like
Reply
Teresa Blunier

Senior Pharmaceutical Sales Representative /Curious Human /Travel Enthusiast

1mo

Exciting times!

Like
Reply
Alan G.E. Wilson

Expert Consultancy in Drug Metabolism, Toxicology, and Pharmacokinetics

3w

Congratulations!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics